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Acetylationoflysinesisaprominentformofmodiﬁcationinmammalianproteins.Deacetylationofproteinsiscatalyzedbyhistone
deacetylases, traditionally named after their role in histone deacetylation, transcriptional modulation, and epigenetic regulation.
Despite the link between histone deacetylases and chromatin structure, some of the histone deacetylases reside in various
compartments in the cytoplasm. Here, we review how these cytoplasmic histone deacetylases are regulated, the identiﬁcation
of nonhistone substrates, and the functional implications of their nondeacetylase enzymatic activities.
1.Introduction
Acetylation is one of the most prominent posttranslational
modiﬁcations aﬀecting the functions of proteins. The ﬁrst
acetylated protein identiﬁed is histone [1]. Twenty-seven
years after this discovery, histone acetyltransferases (HATs)
and histone deacetylases (HDACs) were identiﬁed to be the
enzymes responsible for the acetylation and deacetylation
of lysines of histone proteins [2, 3]. A year later, lysine
modiﬁcation of nonhistone proteins was conﬁrmed with
p53 [4]. Shortly after, many nonhistone proteins were found
to be subject to acetylation/deacetylation (reviewed in [5]).
Remarkably, a recent genome-wide screening for acetylated
proteins shows that lysine acetylation of nonhistone proteins
regulates the formation of large protein complexes with key
roles in major cellular processes [6]. Therefore, lysine acety-
lation, both in histones and nonhistone proteins, appears to
be a salient mode of regulation in the cell.
In mammals, there are eleven protein deacetylases baring
the names HDACs and seven SIRT proteins homologous
to yeast Sir2. The subcellular distribution of these HDACs
is not limited to the nucleus. Some of them, like HDAC6
and HDAC10, are distributed mainly in the cytoplasm, while
SIRT3, 4, and 5 are mitochondrial proteins. A few of them,
including HDAC3, SIRT1, and SIRT2, shuttle between the
nucleus and the cytoplasm. In this paper, we choose to focus
on nonhistone substrates of HDACs, including those in the
nucleus and those in the cytoplasm. We will also discuss
howthesedeacetylasesareregulatedandanynon-deacetylase
functions they might possess.
2.HDAC3
Subcellular localization distinguishes HDAC3 from other
class I HDAC subfamily members. HDAC3 shuttles between
thenucleusandthecytoplasmbyaCRM1-mediatedpathway
[7, 8], suggesting that dynamic localization is a key regulator
of the function of HDAC3. In addition to targeting histones
during interphase (reviewed in [9]), HDAC3 also targets
substrates in the cytoplasm and during mitosis, when the
nuclear envelope breaks down and the distinction between
nucleusandcytoplasmbecomesblurred.Table1summarizes
the subcellular localization and the functions of nonhistone
substrates of HDAC3.
2.1. Nonhistone, Nuclear Substrates of HDAC3
2.1.1.MEF2. MEF2regulatesmyogenesisandotherdevelop-
mental processes, including apoptosis and cardiac hypertro-
phy. It has long been shown to interact with class II HDACs2 Journal of Biomedicine and Biotechnology
such as HDAC4 and HDAC5, but how it is deacetylated
was unclear. It was later found that MEF2 is sumoylated,
not deacetylated, by HDAC4 (discussed in Section 3.4).
Interestingly, the classical HDAC that deacetylates MEF2 was
identiﬁed as HDAC3, and HDAC3 deacetylates MEF2 to
repress the MyoD promoter [10].
2.1.2. Export of SRY and PCAF to the Cytoplasm. HDAC3
aﬀects transcription through a two-fold mechanism: by
deacetylating targets in the nucleus and by promoting their
nuclear exclusion as a result of deacetylation. Deacetylation
of SRY by HDAC3 delocalizes SRY to the cytoplasm [11].
Moreover, HDAC3 promotes translocation of PCAF to the
cytoplasmduringapoptosis[12].CoexpressionHDAC3with
PCAF not only promotes cytoplasmic retention of PCAF but
also that of HDAC3, suggesting a novel interplay between
HDAC3 and PCAF. HDAC3-mediated deacetylation might
reveal nuclear export signals of substrate proteins and help
with their interaction with the CRM1-importin machinery
[7].
2.2. Cytoplasmic Substrates of HDAC3. HDAC3-mediated
deacetylation of STAT1 prevents its phosphorylation, which
is required for nuclear translocation and DNA binding of
STAT1 [13]. In addition, HDAC3 activity also regulates
STAT3 phosphorylation. HDAC3 deacetylates STAT3 at
lysine 685, and an acetylation-resistant mutant of STAT3
loses the dimerization ability [14]. HDAC3 was also found
to form complexes with STAT3 and PP2A to mediate
dephosphorylation of STAT3 [15]. These ﬁndings imply that
HDAC3 might be responsible for the cytoplasmic retention
of STAT3 as well as STAT1. However, factors or signals that
activate HDAC3 remain elusive.
2.3. NF-κB: A Special Substrate of HDAC3 Traversing the
N u c l e u sa n dt h eC y t o p l a s m .HDAC3 deacetylates p65 [16],
one of the two components of the most abundant form
of the NF-κB heterodimer. Deacetylation of p65 at lysine
221 promotes binding of p65 with IκB and rapid nuclear
exportation. Deacetylation of lysine 310, however, impairs
thetranscriptionalactivityofp65withoutchangingitsDNA-
binding activity or nuclear export [17]. Acetylation of p65
was also found on lysines 122/123. Deacetylation of these
two lysines by HDAC3 maintains p65 in an active state in
the nucleus [18]. Interestingly, HDAC3 itself associates with
IκB in the cytoplasm but translocates into the nucleus under
TNF-α-inducedIκBdegradation[19].Theseﬁndingssuggest
that HDAC3 diﬀerentially regulates the activity of NF-κB
through deacetylating diﬀerent lysine residues of p65 and is
regulated by IκB for cytoplasmic retention.
2.4. Regulation of HDAC3 by Phosphorylation. HDAC3 was
found in a protein complex with PP4, and it can be
phosphorylated by CK2 [20]. Biochemically, phosphory-
lation decreases the enzymatic activity of HDAC3 [20].
P P 2 Aa l s of o r m sac o m p l e xw i t hH D A C 3[ 15]. HDAC3 is
phosphorylated at multiple serine/threonine residues during
diﬀerentiation of endothelial progenitors and interacts with
Akt. This interaction promotes phosphorylation of Akt,
increasing its kinase activity [21]. However, despite the
apparentphosphorylationofHDAC3,whetherphosphoryla-
tion changes its subcellular localization, substrate speciﬁcity,
or deacetylase activity in the cytoplasm remains unclear.
More systematic studies are needed to clarify how and why
HDAC3 is regulated by phosphorylation in a physiological
context.
2.5. Association of HDAC3 with the Mitotic Chromosome.
HDAC3 was ﬁrst found to associate with the mitotic
chromosome through immunoaﬃnity puriﬁcation of the
Flag-HDAC3 complex, in which two mitotic chromosome-
associated proteins AKAP95 and HA95 were found [22].
Knockdown of HDAC3 by siRNA blocks histone H3
deacetylation and H3S10 phosphorylation, suggesting H3
modiﬁcation by this complex. However, the role of AKA95
and HA95, most likely in the recruitment of HDAC3 to
the mitotic chromosome, remains unclear. Detailed studies
on the role of HDAC3 in mitosis were further extended
with add-back strategies using wild-type or deacetylase-
dead mutants in HDAC3-knockdown cells. HDAC3 and its
enzyme activity are required for the formation of func-
tional mitotic spindles and proper kinetochore-microtubule
attachment [23]. Fine mapping on chromosomes, using the
same strategies, demonstrates that H3K4 deacetylation by
HDAC3isrequiredforcentromericfunctionsduringmitosis.
Loss of HDAC3 impairs centromeric H3T3 phosphory-
lation, Sgo1 localization, and H3K4 methylation during
mitosis, leading to abnormal sister-chromatid separation
and impaired centromeric functions in mitosis [24]. These
ﬁndings support a novel, nontranscriptional function of
HDAC3inthecytoplasmduringmitosis.Itwillbeinteresting
to know if AKA95, HA95, and Sgo1 are also substrates
of HDAC3. Further identiﬁcation of nonhistone targets
associated with the mitotic chromosome might reveal more
functional links between HDAC3 and mitosis.
2.6. Non Deacetylase Function of HDAC3. Ar e c e n tr e p o r t
about how phosphorylated orphan nuclear receptor TR2
moves to PML nuclear bodies demonstrated that nuclear
relocation of TR2 by HDAC3 is deacetylase independent
using TSA and HDAC3 deacetylase-dead mutants [25]. This
ﬁnding suggests a novel function of HDAC3 as a molecular
chaperone and alludes to a previous report that HDAC3
requires proper folding and priming by a chaperone complex
called TRiC (TCP-1 ring complex) [26]. Geldanamycin, an
inhibitor of chaperone functions, inhibits the formation
of the TRiC-HDAC3 complex [26]. Interestingly, a recent
report showed that TRiC complexes are acetylated [6]. It
remains to be uncovered if the histone deacetylase enzyme
activity of HDAC3 aﬀects the chaperone function of TRiC
and if HDAC3 has innate chaperone activity.
3.HDAC4,5, 7,9
HDAC4, 5, 7, and 9 are classiﬁed into the class IIa subfamily
of HDACs due to similarities in primary structure. Indeed,Journal of Biomedicine and Biotechnology 3
Table 1: Subcellular localization and functions of nonhistone substrates of HDAC3.
Substrates Localization of substrates Functions Comments
MEF2 Nucleus Repression of MyoD promoter
HDAC3 is the only Class I
HDAC that regulates MEF2
activity
SRY Nucleus Nuclear export
Deacetylation leads to
cytoplasmic delocalization
Cytoplasmic translocation
promotes apoptosis
PCAF Nucleus Cytoplasmic retention Functional interplay between
PCAF and HDAC3
STAT1 Cytoplasm Prevention of STAT1
phosphorylation
STAT3 Cytoplasm Prevention of dimerization
NF-κB Cytoplasm or nucleus Cytoplasmic retention or
activation of p65 in the nucleus
Functions are dependent on the
acetylation lysines
they share similar functions in deacetylating histones in
the nucleus and in phosphorylation-regulated subcellular
localization (reviewed in [27, 28]). Recent progress on
HDAC4 and 7 provides us with valuable information on new
substrates, mode of regulation, and novel enzymatic func-
tions of these HDACs. Table 2 summarizes the subcellular
localization and the functions of nonhistone substrates of
HDAC4 and HDAC7.
3.1. Nonhistone, Nuclear Substrates of HDAC4, and HDAC7.
The ﬁrst reported nonhistone protein substrates of HDAC4
are p53 and Runx2. HDAC4 deacetylates lysines at the
C-terminus of p53, resulting in an increase in the tran-
scriptional repression activity of p53 under DNA damage
[29]. Acetylation of Runx2 was found during BMP-2-
stimulated osteoblast diﬀerentiation and bone formation.
HDAC4 mediates deacetylation of Runx2 and promotes
Smurf-mediated degradation of Runx2 [30].
It is reported that HDAC7 shuttles into the nucleus
under hypoxia and functions as a co-repressor for HIF1α
[31]. Although HDAC7 interacts with HIF1α and increases
the transcriptional activity of HIF1α, whether HDAC7
deacetylates HIF1α remains to be determined.
3.2. Cytoplasmic Substrates of HDAC4. Recently three pro-
teins were found to be potential targets for deacetylation
by HDAC4. The Z-disc-associated protein, MLP, can be
acetylated by PCAF and deacetylated by HDAC4 in the
cytoplasm [32], which is important in the regulation of
muscle contraction. HIF1α interacts with HDAC4 and the
cytoplasmic localization of HDAC4 is required for the activ-
ity of HIF1α [33]. As HIF1α is destabilized by acetylation
[34], HDAC4 might help with deacetylation of HIF1α in the
cytoplasm and maintenance of neuronal survival. Moreover,
DNAJB8, which is a cytoplasmic chaperone important for
suppressing cytotoxic protein aggregation, interacts with
HDAC4. Inhibition of HDAC4 reduces the function of
DNAJB8 [35]. More cytoplasmic substrates might be found
for this subfamily of HDACs in the future.
3.3. Regulation of Nucleocytoplasmic Shuttling of HDAC4
and HDAC7. Nucleocytoplasmic shuttling of HDAC4 is
controlled by phosphorylation and dephosphorylation
(reviewed in [28, 36]). Phosphorylated HDAC4 binds to 14-
3-3 and stays in the cytoplasm. This cytoplasmic retention
might be due to preferential binding of phosphorylated
HDAC4 with 14-3-3 in the cytoplasm, resulting in a decrease
in nuclear import [37]. Nuclear import of HDAC4 can
be attained by dephosphorylation of serine 298 by PP2A,
possibly changing the conformation to expose the nuclear
localization signal (NLS) [38]. HDAC4 can also be imported
into the nucleus through interacting with MEF2C by using
MEF2C’s NLS [38, 39]. A recent paper found that HDAC4-
interacting protein DNAJB5 is required for its nuclear
retention as loss of this interaction relocates HDAC4 to the
cytoplasm [40].
In addition to phosphorylation, oxidation also regu-
lates nucleo-cytoplasmic shuttling of HDAC4. Oxidation
of HDAC4 at cysteines 667/669 results in the formation
of intramolecular disulﬁde bonds in response to cardiac
hypertrophy [40]. In this report, overexpression of a newly
identiﬁed HDAC4-interacting protein, Trx1 (Thioredoxin
1), suppresses nuclear export of HDAC4 in response to
reactive oxygen species (ROS) induced by phenylephrine
[40]. It seems that Trx1 regulates the localization of HDAC4
independently of phosphorylation, suggesting multiple ways
to regulate nuclear retention of HDAC4.
Finally, proteolysis might control nuclear import of
HDAC4 [41, 42]. HDAC4 is cleaved at aspartate 289 by cas-
pase processing, leaving behind the C-terminus of HDAC4
in the cytoplasm [42]. The N-terminal portion of HDAC4
possesses an NLS and accumulates in the nucleus. This
fragmentalsorepressesthetranscriptionalactivityofMEF2C
and increases apoptosis [41, 42]. Figure 1 summarizes how
nucleo-cytoplasmic shuttling of HDAC4 is regulated.
HDAC7 shuttles into the nucleus under hypoxia through
an unknown mechanism [43]. It also speciﬁcally localizes to
PML NBs through interacting with PML [44, 45]. Ectopic
expressionofPMLrelievestherepressiveeﬀectofHDAC7on4 Journal of Biomedicine and Biotechnology
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Figure 1: A model on the regulation of nucleo-cytoplasmic shuttling and the functions of HDAC4. HDAC4 dynamically shuttles between
nucleus and cytoplasm, depending on its phosphorylation status. Phosphorylated HDAC4 binds to 14-3-3 and remains in the cytoplasm.
ThecytoplasmicformofHDAC4mightpossessproteindeacetylaseactivity.WhethercytoplasmicHDAC4possessesSUMOE3ligaseactivity
remains unclear. Dephosphorylated HDAC4 is imported into the nucleus, where reduction of HDAC4 by Trx1 favors nuclear retention.
Oxidases that catalyze the reverse reaction remain to be identiﬁed. Nuclear HDAC4 possesses deacetylase as well as SUMO E3 ligase activities
on substrates indicated in the ﬁgure.
Table 2: Subcellular localization and functions of nonhistone substrates of HDAC4 and HDAC7.
Histone deacetylases Substrates Localization of substrates Functions Comments
HDAC4 p53 Nucleus Increases repressional activity of
p53
Under DNA damage
conditions
Runx2 Nucleus Promotes Smurf-mediated
degradation of Runx2
MLP Cytoplasm Regulation of muscle contraction
in cardiac mechanical stretch
HIF1α Cytoplasm Cytoplasmic retention to
maintain neuronal survival
DNAJB8 Cytoplasm Suppression of cytotoxic protein
aggregation
HDAC7 HIF1α Nucleus Corepressor for HIF1α
Deacetylation is not
conﬁrmed for this
interactionJournal of Biomedicine and Biotechnology 5
androgen receptor-mediated transcription by sequestering
HDAC7 into PML NBs [44, 45].
3.4. Sumoylation: A Non-deacetylase Function of HDAC4 and
HDAC7. HDAC4 was found to be sumoylated at lysine 559
[46]. When this lysine is mutated to arginine, HDAC4 loses
its transcriptional repression and histone deacetylase activity
[46]. Interestingly, HDAC4 is also a SUMO E3 ligase in
vivo and in vitro, targeting MEF2 at lysines 439 and 424
[47, 48]. Sumoylation of MEF2 by HDAC4 potentiates the
transcriptional repression activity of MEF2 speciﬁcally for
muscle diﬀerentiation genes [48]. As MEF2 lysine 424 is
acetylated by CBP, these ﬁndings suggest that the transcrip-
tional activity of MEF2 is regulated by a balance between
acetylation and sumoylation, and sumoylation by HDAC4
maypreventlysineacetylation.Recently,additionalsumoyla-
tion substrates have been attributed to HDAC4. Sumoylation
of a transcription factor called ZXDC by HDAC4 enhances
its transcriptional activity [49]. LXR is sumoylated with
SUMO2/3 by HDAC4, which turns LXR into a transcrip-
tional co-repressor regulating programs of gene expression
that control immunity and homeostasis [50]. LXRα,b u t
not LXRβ, speciﬁcally associates with the STAT1/HDAC4
complex, whereas HDAC4 promotes sumoylation of LXRα.
Furthermore, sumoylation of LXRα is required for the
suppressionofSTAT1-dependentinﬂammatoryresponsesby
LXRs in brain astrocytes stimulated with IFN-γ [51].
HDAC7 was reported to facilitate transcriptional repres-
sion in a deacetylase-independent manner [52], which might
be a result of sumoylation of HDAC7-interacting proteins.
HDAC7 associates with PML, promoting sumoylation of
P M La sw e l la st h ef o r m a t i o no fP M LN B s[ 53]. It is
possible that the putative E3 enzyme activity of HDAC7 is
important for the regulation of androgen receptor-mediated
transcription (compare Section 3.3).
4.HDAC6and10
HDAC6isacytoplasmic,classIIbHDAC.Mostofthestudies
focus on its substrate tubulin and how (de)acetylation of
tubulin aﬀects lymphocyte chemotaxis, cellular adhesions,
aggresome formation, EGFR signaling, HIV infection, stress
granules in stress response, and growth factor-induced actin
remodeling and endocytosis (reviewed in [54–58]). Here, we
focus on recent identiﬁcation of novel HDAC6 substrates,
regulation of HDAC6 deacetylase activity through protein-
protein interactions (summarized in Figure 2 and Table 3),
and the biological function of a close relative of HDAC6,
HDAC10.
4.1. Cytoplasmic Substrates of HDAC6
4.1.1. Hsp90. Hsp90 was the second HDAC6 substrate
identiﬁed in the cytoplasm after tubulin. Although Hsp90
can be acetylated at diﬀerent lysines, HDAC6 speciﬁcally
deacetylates lysine 294 of Hsp90 [64]. Deacetylation of this
lysinedecreasesthechaperonefunctionofHsp90,speciﬁcally
Hsp90’s interaction with cochaperone p23 and client pro-
tein glucocorticoid receptor (GR) ([65]; reviewed in [54]).
Deacetylation of Hsp90 by HDAC6 results in retention of
p23 and GR in the cytoplasm, failure of GR maturation, and
decreased transcription of target genes. This model is further
examined in aryl hydrocarbon receptor (AhR) signaling.
Inhibition of HDAC6 blocks the formation of the chaperone
complex containing Hsp90, AhR, p23, and XAP-2 as well as
the activation of downstream target genes [66].
4.1.2. Cortactin. HDAC6 deacetylates cortactin, an F-actin-
binding protein. Deacetylation of cortactin increases its
interaction with F-actin [67]. A mutation of cortactin that
mimics acetylation prevents its localization to membrane
ruﬄes and inhibits cell motility. HDAC6 knockdown causes
the same eﬀect [67]. Based on these ﬁndings, Lee and his
colleagues found that deacetylation of cortactin by HDAC6
is important for autophagy ([68]; reviewed in [69]).
4.1.3. β-Catenin. β-catenin is found to be acetylated at lysine
49 [70], which is frequently mutated in anaplastic thyroid
cancer. Acetylation of lysine 49 blocks phosphorylation of
serine 45 of β-catenin [70] ,w h i c hp r o m o t e si t sd e g r a -
dation [71, 72]. Therefore, HDAC6 inactivation inhibits
EGF-induced nuclear translocation β-catenin, resulting in
inhibition of cellular growth [70]. This ﬁnding suggests a
new role of HDAC6 in the regulation of speciﬁc signal
transduction pathways.
4.1.4. Peroxiredoxins. Peroxiredoxin (Prx) I and Prx II are
antioxidants that reduce H2O2, a process important in the
modulation of intracellular redox status. Deacetylation of
PrxIandPrxIIbyHDAC6leadstoapoptosis[73],suggesting
that HDAC6 regulates stress response by altering redox
homeostasis.
4.2. Regulation of HDAC6 by Protein-Protein Interaction.
Unlike class IIa HDAC members, HDAC6 has not been
showntoberegulatedthroughnucleo-cytoplasmicshuttling.
Interestingly, several recent reports describe that HDAC6
enzymatic activity is negatively regulated by protein-protein
interaction partners (Figure 2 and Table 3), [59–63]. For
example, interaction with IIp45 renders HDAC6 unstable
[61], while EGFR signaling results in HDAC6 phosphory-
lation at tyrosine 570, reducing its deacetylase activity [63].
Studies from these newly identiﬁed HDAC6-interacting pro-
teins suggest that, in addition to direct chemical inhibition,
HDAC6 can be subject to regulation by extracellular and
intracellular stimuli.
4.3. HDAC10: An Enigmatic Relative of HDAC6. While
HDAC6 plays multiple roles in the cytoplasm, very little
is known about another cytoplasmic deacetylase, HDAC10,
which is closest to HDAC6 (reviewed in [55]). Recently,
HDAC10 is shown to target nonhistone substrates both in
the nucleus and the cytoplasm [74]. Using immunoaﬃnity
puriﬁcation, Hsp70 was identiﬁed as the most abundant
proteinassociatedwithHDAC10andHDAC10onlyinteracts
with a deacetylated form of Hsp70, suggesting that HDAC10
might contribute to the deacetylation status of Hsp70 [74].6 Journal of Biomedicine and Biotechnology
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Figure 2: Regulation and functional ramiﬁcations of the HDAC6 deacetylase activity. Interaction with protein partners reduces protein
deacetylase activity of HDAC6, which is important for the deacetylation of substrate proteins and cellular eﬀects as indicated.
Table 3: Proteins interacting with and inhibiting the deacetylase activity of HDAC6.
Interacting proteins Substrates aﬀected Functions involved References
TPPP/p25 Tubulin Decrease cell mobility [59]
CYLD Tubulin Cell proliferation [60]
IIp45 Tubulin (decreases stability of HDAC6) Cell migration [61]
Tau Tubulin Prevent autophagy [62]
EGFR Tubulin (decreases deacetylase activity of
HDAC6 by phosphorylation)
Decrease endocytosis and
degradation
[63]
Using a speciﬁc histone deacetylase inhibitor FK228 to treat
K562 cells, acetylation of Hsp70 is increased while that
of Hsp90 remains unchanged [75]. Interestingly, acetylated
Hsp70 speciﬁcally interacts with c-Abl and Bcr-Abl in K562
cells,promotingBcr-Abldegradation[75].Theseresultssug-
gest that acetylation of Hsp70, which possibly results from
deregulation of HDAC10 rather than HDAC6, might cause
incorrect folding of substrate proteins in the cytoplasm and
subsequent degradation (Figure 3). Furthermore, HDAC10
might target nonhistone proteins important in transcrip-
tional regulation. HDAC10 interacts with deacetylated forms
of Pax3 and KAP1, resulting in derepression of Pax3 target
genes during melanogenesis [74]. These lines of evidence
suggest that, like HDAC6, HDAC10 has nonhistone targets
in both the nucleus and the cytoplasm. Full revelations
of the physiologic functions of HDAC10 will come from
identiﬁcation of additional HDAC10 targets.
5.SIRT1–5
Sir2 is an NAD+-dependent deacetylase that extends life
span in yeast. Mammalian SIRT proteins, or sirtuins, are
yeast Sir2 homologs that regulate diverse processes including
life span, energy metabolism, stress response, DNA repair,
and tumorigenesis. Seven mammalian SIRT proteins have
been identiﬁed to date. Most reviews focus on SIRT1, the
closest relative of yeast Sir2, and SIRT2 (for a very recent
review on SIRT1 and 2, see [76]). Mitochondrial sirtuins
are usually reviewed separately [77–79]. In this section, we
will brieﬂy discuss the functions of SIRT1 and SIRT2 in the
cytoplasm as their general (nuclear) functions are extensively
reviewedintheliterature,summarizethefunctionsofSIRT3,
4, 5 that reside in the mitochondrion, and omit chromatin-
associating SIRT6 and nucleolar-residing SIRT7. For a con-
cise overview of the function of all seven sirtuins, readers are
referredtorecentreviewssuchas[80–82].Table4summaries
thesubstratesandthefunctionsofthesecytoplasmicsirtuins.
5.1. SIRT1. The subcellular localization of SIRT1 is cell type
dependent. Studies using cell lines and animals show that in
somecellsSIRT1ispredominatelynuclearwhileinothersitis
predominatelycytoplasmic[83,84].Twonuclearlocalization
signals and two nuclear export signals have been identiﬁed in
SIRT1 [83, 84]. Cytoplasmic localization of SIRT1, mediatedJournal of Biomedicine and Biotechnology 7
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Figure 3: A model of how HDAC6/Hsp90 and HDAC10/Hsp70 collaboratively work as protein chaperones. Deacetylation of Hsp90
catalyzed by HDAC6 might prime its chaperone function. Deacetylated Hsp70, catalyzed by HDAC10 or by another deacetylase, joins the
Hsp90/chaperone client complexes to help with correct folding of the clients. Acetylation of Hsp70, a likely result of HDAC10 deregulation,
might cause incorrect folding of proteins or facilitate the subsequent degradation of misfolded proteins.
by a CRM1-dependent nuclear export pathway, might be
regulated by diﬀerentiation [83]. However, the cytoplasmic
presence of SIRT1 has also been linked to a propensity for
apoptosis, as cytoplasmic translocation of nuclear SIRT1
increases apoptosis [83, 84].
Questions remain about the physiologic signiﬁcance
of cytoplasmic SIRT1 as well as the detailed mechanism
of apoptotic regulation by cytoplasmic translocation of
SIRT1. It has been shown, almost a decade ago, that SIRT1
suppresses stress-induced apoptosis by deacetylating p53
[85, 86]. In studies using mammalian cells and tissues,
cytoplasmic SIRT1 promotes apoptosis induced by oxidative
stress and nocodazole, a metaphase apoptosis inducer [83,
84]. These results suggest that elucidation of how SIRT1
responds to cellular stress and then translocates to the
cytoplasm will be key to full understanding of how SIRT1
regulates apoptosis.
In genetic assays using C. elegans, it appears that SIR-2.1,
the worm homolog of SIRT1, also induces apoptosis in a
manner that depends on its cytoplasmic translocation from
the nucleus [87]. However, this study shows that SIR-2.1
speciﬁcally activates the apoptotic program induced by DNA
damage in germ cells [87]. It will be interesting to ﬁnd out
whether the diﬀerences in the worm study and the studies
in mammalian cells are a result of experimental design, or
SIRT1-mediated apoptosis indeed has inherent speciﬁcity.
5.2. SIRT2. SIRT2 is predominately cytoplasmic [88], with
nuclear-cytoplasmic shuttling reported [89, 90]. The biolog-
ical function of SIRT2 was ﬁrst revealed by the identiﬁcation
that SIRT2 is an NAD+-dependent deacetylase speciﬁc for α-
tubulin [88]. A number of nuclear substrates deacetylated
by SIRT2 has also been identiﬁed, including p53, FOXO1,
FOXO3a,histoneH4,histoneH3,andp300[91–96],whereas
the biological signiﬁcance of these nuclear substrates will
be excluded from the discussion here. The deacetylase
activity of SIRT2 is modulated by phosphorylation and
acetylation, although the exact subcellular localization of
these modiﬁcations remains unspeciﬁed. Phosphorylation
of the SIRT2 protein at serine 368, which inhibits SIRT28 Journal of Biomedicine and Biotechnology
Table 4: Cytoplasmic sirtuins, their substrates in the cytoplasm, and their functions.
Mammalian cytoplasmic
sirtuins Substrates Functions Comments
SIRT1 (subcellular
localization is cell type
dependent)
Cytoplasmic localization of
SIRT1 is linked to apoptosis
Whether SIRT1 enhances or decreases
apoptosis and the mechanistic details
remain unclear
SIRT2 (shuttles between
nucleus and cytoplasm) α-tubulin
Mitotic exit of normal cell
cycle
Regulation of mitotic
checkpoint under stress
Neuronal motility and
diﬀerentiation
Subcellular localization of SIRT2
modiﬁcations that modulate
deacetylase activity of SIRT2, namely,
phosphorylation and acetylation, is
largely unspeciﬁed
Mechanism(s) through which SIRT2
regulates mitotic exit remains unclear
SIRT3
(in mitochondria)
AceCS2
GDH
ICDH2
Complex I of electron transport
chain
Ku70
Nampt
MRPL10
Regulation of energy
metabolism and apoptosis
GDH activity is not signiﬁcantly
altered in Sirt3 knockout mice
SIRT4
(in mitochondria)
GDH
(SIRT4 also interacts with ANT2,
SIRT3, and IDE)
Regulation of insulin
secretion
SIRT4 is an ADP ribosylase
No deacetylase activity is reported for
SIRT4
ADP-ribosylation of ANT2, SIRT3, or
IDE by SIRT4 has not been shown
deﬁnitely
SIRT5
(in mitochondria) CPS1 cytochrome c Regulation of urea cycle
Promotes apoptosis?
Exact submitochondrial localization of
SIRT5, how calorie restriction alters
CPS1 acetylation through SIRT5, and
what lysines in CPS1 are acetylated
under diﬀerent nutrient availability
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activity, is mediated by cyclin-dependent kinases Cdk1,
Cdk2, and Cdk5 [97, 98]. Dephosphorylation of SIRT2 is
attributed to CDC14B [97, 99]. Acetylation of SIRT2 by
p300, which is also a substrate of SIRT2, downregulates the
activity of SIRT2 [100]. SIRT2 also interacts with HDAC6,
HOXA10,14-3-3β/γ,andmembersoftheDNAJBchaperone
family [35, 88, 92, 101].
Compared with other mammalian sirtuins, SIRT2
expressesabundantlyinthebrain[98,102].GiventhatSIRT2
deacetylates α-tubulin, SIRT2 might be instrumental in the
regulation of neuronal processes involving microtubules,
such as neurite outgrowth, dynamics of cytoskeletal growth
cones, oligodendrocyte arborization, and migration of
glioma (reviewed in [103]). SIRT2 has also been implicated
in the proliferation of gliomas [104]. Further studies show
that SIRT2 regulates mitotic exit from the normal cell cycle
aswellasmitoticcheckpointsundermitoticstressinducedby
microtubule inhibitors ([99, 105, 106] and reviewed in [82]).
SIRT2 has been implicated in the regulation of mitotic
exit. It accumulates during G2/M transition, and over-
expressed SIRT2 prolongs mitosis [99, 101]. Further-
more,microinjectionofO-acetyl-ADP-riboseformedduring
SIRT2-mediated deacetylation or low amounts of human
SIRT2 blocks starﬁsh oocyte maturation [107]. It is postu-
lated that a decrease in the amount or enzymatic activity
of SIRT2 is required for proper mitotic exit. Findings
showing how SIRT2 is regulated by cyclin-dependent kinases
and CDC14B, which is important for cytokinesis, seem to
support this hypothesis. However, the detailed mechanism
of how SIRT2 regulates mitotic exit remains elusive.
Studies from the Oshimura group further found that
SIRT2 blocks chromosome condensation in the presence of
microtubule poisons such as nocodazole, enabling a mitotic
checkpoint [105, 106], a phenomenon previously ascribed to
theprophasecheckpointproteinCHFR[108].SIRT2appears
to be necessary to rescue cells from prolonged mitotic
arrest and to avoid secondary outcomes such as cell death
and hyperploidy that usually accompany release from such
mitotic arrest [106]. Furthermore, downregulation of SIRT2
using siRNA causes centrosome fragmentation before the
activation of the mitotic checkpoint elicited by nocodazole
[106]. These results suggest that SIRT2 is crucial in the
regulation of mitotic checkpoints and centrosome integrity.
5.3. SIRT3. SIRT3 is a mitochondrial matrix protein that
regulates mitochondrial protein acetylation [109–111], andJournal of Biomedicine and Biotechnology 9
its N-terminal mitochondrial targeting sequence needs to be
removed for full deacetylase activity [111, 112]. It has been
suggested that SIRT3 might translocate to the nucleus [113–
115], and the nuclear presence of SIRT3 requires both the
mitochondrial targeting signal as well as the putative nuclear
localization signal [113]. The physiological signiﬁcance of
the presence of SIRT3 in the nucleus, the mitochondrion,
or even the cytoplasm remains controversial (reviewed in
[116]). Some studies suggest that it depends on whether the
SIRT3 protein is proteolytically processed [115], as both a
long form and a short form of the SIRT3 protein have been
reported [117–120] and cleavage of SIRT3 aﬀects subcellular
location [115].
The substrates of SIRT3 known to date fall into two
categories: those involved in energy metabolism and those
involved in apoptosis. The former group includes acetyl-
coenzyme A synthase 2 (AceCS2) [111, 121], glutamate
dehydrogenase (GDH) [79], isocitrate dehydrogenase 2
(ICDH2) [79], and Complex I of the electron transport
chain [122]. The latter includes Ku70 [115], nicotinamide
phosphoribosyltransferase (Nampt) [123], and MRPL10
(mitochondrial ribosomal protein L10) [124].
Deacetylation of AceCS2 at lysine 642 by SIRT3 activates
the enzymatic activity of AceCS2 [111, 121], which converts
acetate into acetyl-CoA [125]. GDH converts glutamate
to α-ketoglutarate [126]. In vitro deacetylation of GDH
by SIRT3 activates its activity by 10% [79], and GDH is
hyperacetylated in Sirt3 knockout mice [109]. However,
GDH activity is not signiﬁcantly altered in Sirt3 knockout
mice [127]. SIRT3 deacetylates and activates the activity
of ICDH2 in vitro in a dose-dependent manner [79].
ComponentsoftheelectrontransportchainComplexIshow
increasedacetylationlevelsanddecreasedactivityinSirt 3
−/−
cells [122]. SIRT3 also physically interacts with the NDUFA9
subunit of Complex I [122].
In cardiomyocytes, SIRT3 deacetylates Ku70 and pro-
motesassociationbetweenKu70andBax,therebypreventing
Bax-mediated apoptosis [115]. Studies using siRNA show
that SIRT3 (and SIRT4) is required for Nampt-mediated
protection against methylmethane sulfonate-induced cell
death [123]. Nampt catalyzes the rate-limiting step in NAD+
biosynthesis from NAM [128, 129] and is upregulated by
fasting or cell stress [123]. Upregulation (an increase in
protein amount) of Nampt by nutrient deprivation might
be a result of SIRT3-mediated deacetylation and activa-
tion of mitochondrial ribosomal protein MRPL10, which
enhances mitochondrial protein synthesis [124]. Interest-
ingly, angiotensin II (Ang II) downregulates the mRNA level
of Sirt3, and this downregulation is inhibited by application
o fa na n t a g o n i s tt oA n gI It y p e1r e c e p t o r[ 130]. These
results suggest that SIRT3 promotes longevity and cellular
response to diﬀerent forms of stress through a multiple of
mechanisms. However, as SIRT3 is also reported as a pro-
apoptoticfactor[131],theroleofSIRT3inapoptosisrequires
additional evidence to clarify.
5.4. SIRT4. SIRT4 resides in the mitochondrial matrix
[132–134]. SIRT4 has not been shown to possess protein
deacetylase activity. Instead, it ADP ribosylates glutamate
dehydrogenase (GDH) [133]. In mitochondria, GDH cat-
alyzes the conversion of glutamate to α-ketoglutarate, which
subsequently enters the tricarboxylic acid cycle [126]. ADP
ribosylationbySIRT4inhibitstheenzymaticactivityofGDH
and hinders the metabolism of glutamine and glutamate
to generate ATP [133]. As a result, SIRT4 represses insulin
secretion of pancreatic β cells in response to glucose and
amino acids.
Further evidence that SIRT4 regulates insulin secretion
comes from the ﬁnding that SIRT4 associates with adenine
nucleotide translocator 2 (ANT2) [132]. Metabolites from
glycolysis and tricarboxylic acid cycle fuel the production
of ATP through oxidative phosphorylation, which leads
to an increase in the level of ATP in the mitochondrial
matrix. ATP/ADP translocators such as ANT2 facilitate
exchange of mitochondrial ATP for cytosolic ADP, causing
anincreaseofthecytosolicATP/ADPratio.Inresponse,ATP-
sensitiveK+ channelsclose,whichleadstoplasmamembrane
depolarization and opening of the voltage-dependent Ca2+
channels. The resulting ﬂux of intracellular Ca2+ prompts
insulin exocytosis (reviewed in [135]). Therefore, ﬁndings
that SIRT4 ADP ribosylates GDH and interacts with ANT2
strongly support a role of SIRT4 in the regulation of insulin
secretion. An inverse relationship between GDH activity and
ADP-ribosylation is also observed during calorie restriction
(CR) in that hepatic GDH activity is elevated while the level
of ADP-ribosylation of GDH is decreased [133]. Interest-
ingly, CR induces amino acid-stimulated insulin secretion
in pancreatic islets [133, 136]. These phenomena allude to
previous ﬁndings that, during CR, amino acids serve as
carbon sources [136, 137]. However, they do not explain the
need to upregulate the activity of GDH and the secretion of
insulin during CR.
The studies surrounding GDH and insulin secretion
inevitably raise the question of how the ADP-ribosylase
activity of SIRT4 is regulated. Unfortunately, there is no
clear answer to that question. However, SIRT3, another
mitochondrial sirtuin that interacts with Complex I of the
electron transport chain [122] and shows weak deacetylase
activity toward GDH [79], interacts with SIRT4 [132].
SIRT4 also interacts with insulin-degrading enzyme (IDE),
although it has not been shown clearly whether IDE can be
ADP-ribosylated by SIRT4 [132]. It is tempting to speculate
that the activity of SIRT4 is regulated by another sirtuin,
perhaps by NAD+-dependent deacetylation or by a certain
kind of insulin-sensing mechanism. Further experimental
support is needed to answer these questions.
5.5. SIRT5. The N-terminal 36 amino acids of SIRT5 are
removed after SIRT5 is imported into the mitochondrial
matrix [127, 138]. However, debates remain surrounding the
exact location of SIRT5 in the mitochondrion. Endogenous
murine SIRT5 shows exclusive matrix localization [127].
However, overexpressed SIRT5 is located in the mitochon-
drial intermembrane space (IMS) in COS7 cells [113]. To
add to the confusion, in vitro import assay using isolated
yeast mitochondria shows that human SIRT5 is imported
into both the IMS and the matrix [79]. There is also a
report showing that SIRT5 exists in both the nucleus and10 Journal of Biomedicine and Biotechnology
the cytoplasm [139]. To fully understand the physiological
signiﬁcance as well as regulation of SIRT5, the exact cellular
location of this sirtuin needs to be determined.
The in vivo substrate of SIRT5 has recently been
identiﬁed as carbamoyl phosphate synthase 1 (CPS1) in
an immunocapture screen for SIRT5-interacting partners
[127]. CPS1 is the committed enzyme of the urea cycle,
which is important for the removal of excess ammonia
[140, 141]. Excess ammonia is generated during fasting or
as a result of high-protein diet [141–144]. Activation of
CPS1 by SIRT5 is, therefore, crucial for the conversion of
ammonia into carbamoyl phosphate, and ultimately, urea.
NAD+-dependent deacetylation of CPS1 by SIRT5 activates
the enzymatic activity of CPS1 in vitro, and CPS1 activity is
decreasedinSirt5knockoutmice[127].Nutrientdeprivation
induces CPS1 activity in normal primary hepatocytes [127].
More importantly, during starvation, Sirt5 knockout mice
show higher levels of blood ammonia, lower CPS1 activity,
and higher levels of CPS1 acetylation compared with wild-
type animals [127]. However, in Sirt 5
−/− cells, CPS1 activity
is less sensitive to nutrient deprivation treatment [127].
It appears that CR for 6 months brings about a decreased
level of CPS1 acetylation in normal mice, lower than that
observed for animals fed ad libitum but higher than in fasted
animals [127]. However, the acetylation level of CPS1 has
also been reported to be increased by CR [145]. Potential
controversy exists regarding the level and particular lysines
acetylated in CPS1 in response to varied nutrient availability
(discussed in [78]). Along the lines of energy metabolism,
it has been shown that the mitochondrial level of NAD+
increases about twofold while that of NADH remains
constant during fasting, and SIRT5 activity is stimulated by
NAD+ with a Km of 50–100μMi nv i t r o[ 127]. Moreover,
ethanol causes a decrease in both NAD+ level [146] and the
activity of SIRT5 [147]. These ﬁndings raise the possibility
that SIRT5 is regulated by the level of NAD+.H o w e v e r ,a s
NAD+ aﬀectstheactivityofmanysirtuins,morebiochemical
analysis is needed to discriminate the diﬀerences between
sirtuins in their response to NAD+ levels.
In addition to CPS1, cytochrome c has been reported
to be deacetylated by SIRT5 in an ELISA-based system and
colocalizes with SIRT5 in the IMS [79]. It is possible that
SIRT5-mediated deacetylation contributes to the regulation
of the proapoptogenic activity of cytochrome c. Further-
more, overexpressed and mitochondrially localized SIRT5
promotes apoptosis in cerebellar granule neurons and in
HT-22 neuroblastoma cells [139]. The role of SIRT5 in
apoptosis no doubt depends on its exact subcellular location,
and the causal relationship between SIRT5 and apoptosis
remains to be clariﬁed.
6. Concluding Remarks
Acetylation is a rather common form of post-translational
modiﬁcation [6]. However, when, how, and which deacety-
lases regulate the acetylation status of proteins remain largely
unknown. Recent studies about HDAC3 and NF-κB also
remind us that deacetylation of diﬀerent lysines on the
same substrate protein can have divergent consequences.
Therefore, the ﬁeld of protein acetylation is far from mature.
Future advances will likely come from understanding of
how the activity of deacetylases is regulated as well as
identiﬁcation of novel, non-deacetylase activities. We now
know that multiple inputs, coming from interactions with
cytoplasmic proteins, are integrated into HDAC6 to regulate
its deacetylase activity. Moreover, HDAC4 and HDAC7
participate in protein sumoylation, while HDAC3 might
function as a protein chaperone. Similar discoveries will
further enlighten us on this fascinating group of proteins
and clarify some of the controversies surrounding the
mechanistic details of mammalian sirtuins.
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